Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HE009
- Development stage
- Phase 2
- Lead developer
- Nanchang Hongyi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HE009 is an orally administered small molecule antagonist of the sphingosine-1-phosphate receptor 1 (S1PR1). It is being developed by Nanchang Hongyi Pharmaceutical for potential therapeutic use. The drug's primary mechanism involves blocking S1PR1, a receptor involved in immune cell trafficking and vascular integrity, which may have applications in autoimmune or inflammatory diseases. As of the latest available data, HE009 has completed Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects[1][2].
02
Targets
EDG1 (Sphingosine-1-phosphate receptors)
Beyond the preview
Go deeper on HE009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HE009.